vs

Side-by-side financial comparison of Community West Bancshares (CWBC) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

Community West Bancshares is the larger business by last-quarter revenue ($38.3M vs $38.3M, roughly 1.0× ImmunityBio, Inc.). On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 11.6%). Community West Bancshares produced more free cash flow last quarter ($43.6M vs $-71.3M).

Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CWBC vs IBRX — Head-to-Head

Bigger by revenue
CWBC
CWBC
1.0× larger
CWBC
$38.3M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+395.4% gap
IBRX
407.0%
11.6%
CWBC
More free cash flow
CWBC
CWBC
$114.9M more FCF
CWBC
$43.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CWBC
CWBC
IBRX
IBRX
Revenue
$38.3M
$38.3M
Net Profit
$-61.9M
Gross Margin
99.0%
Operating Margin
40.0%
-169.0%
Net Margin
-161.8%
Revenue YoY
11.6%
407.0%
Net Profit YoY
-4.7%
EPS (diluted)
$0.58
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWBC
CWBC
IBRX
IBRX
Q4 25
$38.3M
$38.3M
Q3 25
$37.9M
$32.1M
Q2 25
$35.7M
$26.4M
Q1 25
$34.8M
$16.5M
Q4 24
$34.3M
$7.6M
Q3 24
$31.3M
$6.1M
Q2 24
$30.5M
Q1 24
$20.7M
Net Profit
CWBC
CWBC
IBRX
IBRX
Q4 25
$-61.9M
Q3 25
$10.9M
$-67.3M
Q2 25
$7.8M
$-92.6M
Q1 25
$8.3M
$-129.6M
Q4 24
$-59.2M
Q3 24
$3.4M
$-85.7M
Q2 24
$-6.3M
Q1 24
$3.7M
Gross Margin
CWBC
CWBC
IBRX
IBRX
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CWBC
CWBC
IBRX
IBRX
Q4 25
40.0%
-169.0%
Q3 25
39.8%
-173.5%
Q2 25
30.2%
-269.8%
Q1 25
32.7%
-390.1%
Q4 24
31.0%
-919.0%
Q3 24
13.3%
-1314.3%
Q2 24
-25.9%
Q1 24
23.2%
Net Margin
CWBC
CWBC
IBRX
IBRX
Q4 25
-161.8%
Q3 25
28.7%
-209.8%
Q2 25
22.0%
-350.3%
Q1 25
23.8%
-784.9%
Q4 24
-783.4%
Q3 24
10.8%
-1404.0%
Q2 24
-20.7%
Q1 24
17.8%
EPS (diluted)
CWBC
CWBC
IBRX
IBRX
Q4 25
$0.58
$-0.06
Q3 25
$0.57
$-0.07
Q2 25
$0.41
$-0.10
Q1 25
$0.44
$-0.15
Q4 24
$0.29
$-0.08
Q3 24
$0.18
$-0.14
Q2 24
$-0.33
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWBC
CWBC
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$119.0M
$242.8M
Total DebtLower is stronger
$69.5M
Stockholders' EquityBook value
$409.6M
$-500.5M
Total Assets
$3.7B
$501.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWBC
CWBC
IBRX
IBRX
Q4 25
$119.0M
$242.8M
Q3 25
$121.6M
$257.8M
Q2 25
$134.4M
$153.7M
Q1 25
$148.4M
$61.6M
Q4 24
$120.4M
$149.8M
Q3 24
$149.0M
$130.4M
Q2 24
$109.7M
Q1 24
$61.0M
Total Debt
CWBC
CWBC
IBRX
IBRX
Q4 25
$69.5M
Q3 25
Q2 25
Q1 25
Q4 24
$69.9M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CWBC
CWBC
IBRX
IBRX
Q4 25
$409.6M
$-500.5M
Q3 25
$397.6M
$-524.3M
Q2 25
$380.0M
$-570.7M
Q1 25
$372.2M
$-591.4M
Q4 24
$362.7M
$-489.1M
Q3 24
$363.5M
$-745.1M
Q2 24
$350.2M
Q1 24
$211.7M
Total Assets
CWBC
CWBC
IBRX
IBRX
Q4 25
$3.7B
$501.9M
Q3 25
$3.6B
$519.0M
Q2 25
$3.6B
$402.1M
Q1 25
$3.6B
$303.8M
Q4 24
$3.5B
$382.9M
Q3 24
$3.5B
$364.6M
Q2 24
$3.5B
Q1 24
$2.4B
Debt / Equity
CWBC
CWBC
IBRX
IBRX
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
0.19×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWBC
CWBC
IBRX
IBRX
Operating Cash FlowLast quarter
$46.1M
$-70.4M
Free Cash FlowOCF − Capex
$43.6M
$-71.3M
FCF MarginFCF / Revenue
113.9%
-186.2%
Capex IntensityCapex / Revenue
6.6%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$77.7M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWBC
CWBC
IBRX
IBRX
Q4 25
$46.1M
$-70.4M
Q3 25
$13.2M
$-68.9M
Q2 25
$11.5M
$-79.7M
Q1 25
$11.1M
$-85.9M
Q4 24
$22.2M
$-85.1M
Q3 24
$7.8M
$-98.8M
Q2 24
$5.2M
Q1 24
$4.0M
Free Cash Flow
CWBC
CWBC
IBRX
IBRX
Q4 25
$43.6M
$-71.3M
Q3 25
$12.8M
$-69.6M
Q2 25
$10.6M
$-80.8M
Q1 25
$10.8M
$-87.0M
Q4 24
$17.2M
$-87.3M
Q3 24
$5.2M
$-101.6M
Q2 24
$4.8M
Q1 24
$3.6M
FCF Margin
CWBC
CWBC
IBRX
IBRX
Q4 25
113.9%
-186.2%
Q3 25
33.7%
-217.2%
Q2 25
29.6%
-305.9%
Q1 25
30.9%
-526.9%
Q4 24
50.0%
-1155.4%
Q3 24
16.7%
-1663.2%
Q2 24
15.7%
Q1 24
17.3%
Capex Intensity
CWBC
CWBC
IBRX
IBRX
Q4 25
6.6%
2.4%
Q3 25
1.1%
2.3%
Q2 25
2.7%
4.1%
Q1 25
0.9%
6.8%
Q4 24
14.7%
28.0%
Q3 24
8.1%
45.7%
Q2 24
1.4%
Q1 24
2.1%
Cash Conversion
CWBC
CWBC
IBRX
IBRX
Q4 25
Q3 25
1.21×
Q2 25
1.47×
Q1 25
1.33×
Q4 24
Q3 24
2.29×
Q2 24
Q1 24
1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons